The final cost was still being determined.
Earlier in the day, PhRMA, the pharmaceutical industry's main lobbying group, sought to distance itself from Turing's move, posting on Twitter that the drugmaker "does not represent the values of PhRMA member companies."
Asked for further details, the lobby group noted that Turing is not one of its members, which include global drugmakers such as Merck, Pfizer (which has been accused of price gouging for an epilepsy drug) and Novartis. "Turing Pharmaceutical is not a member of PhRMA and we do not embrace either their recent actions or the conduct of their CEO.”
Shkreli had defended the price hike in an interview on CNBC saying that Daraprim had been priced too low and that his company needed to generate profits that it would spend on new research and development.
Asked if he would lower the price in response to the furor, Shkreli simply responded, "No."
Al Jazeera with wire services